T-cadherin as a key regulator of metabolism in health and disease

T-cadherin (also known as cadherin 13, H-cadherin (heart), and CDH13) is a multifunctional protein that plays a key role in metabolism regulation, adipogenesis, and carcinogenesis. The review presents current perspectives on the structure and functions of T-cadherin, interaction with its well-known ligands (adiponectin, and low-density lipoproteins (LDL)). Special attention is given to analysing the role of T-cadherin in adipogenic differentiation of mesenchymal stromal/stem cells (MSCs), as well as its effects on lipid accumulation and the maintenance of metabolic homeostasis. It is suggested that T-cadherin may act as a sensor of metabolic signals, regulating the balance between adipogenesis and the activation of stem/progenitor cells, which is crucial for maintaining cellular homeostasis in adipose tissue.

In the context of oncological diseases, T-cadherin functions as a potential tumor suppressor. Loss of T-cadherin expression is a hallmark of many cancers, including breast, lung, and colorectal cancer. Reduced levels of T-cadherin are associated with hypermethylation of the CDH13 gene promoter or loss of heterozygosity in the CDH13 gene region. T-cadherin may also mediate the protective effects of adiponectin, which has oncosuppressive properties. Imbalances between adiponectin and LDL in obesity and metabolic syndrome may contribute to the development of oncological diseases. Thus, T-cadherin may mediate the link between obesity and carcinogenesis. Its ability to regulate adipogenesis and interact with ligands affecting overall metabolism, makes this protein a promising target for further research. Understanding the molecular mechanisms mediated by T-cadherin may open new avenues to treatment of obesity and related oncological diseases.

1. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. (2013) 291546. DOI: 10.1155/2013/291546

2. Xiao M, Xu J, Wang W, Zhang B, Liu J, Li J, et al. Functional significance of cholesterol metabolism in cancer: from threat to treatment. Exp Mol Med. 2023;55(9):1982–1995. DOI: 10.1038/s12276-023-01079-w

3. Gu J, Zhu N, Li HF, Zhao TJ, Zhang CJ, Liao DF, et al. Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor. Cell Oncol (Dordr). 2022;45(5):709–728. DOI: 10.1007/s13402-022-00694-5

4. Rubina KA, Semina EV, Kalinina NI, Sysoeva VY, Balatskiy AV, Tkachuk VA. Revisiting the multiple roles of T-cadherin in health and disease. Eur J Cell Biol. 2021;100(7–8):151183. DOI: 10.1016/j.ejcb.2021.151183

5. Vestal DJ, Ranscht B. Glycosyl phosphatidylinositol-anchored T-cadherin mediates calcium-dependent, homophilic cell adhesion. J Cell Biol. 1992;119(2):451–461. DOI: 10.1083/jcb.119.2.451

6. McWilliam, J. Cadherins types, structure and functions. Nova Science Publishers, 2020. 415 p.

7. Рубина КА, Ткачук ВА Навигационные рецепторы в нервной и сердечно-сосудистой системах. Biochemistry (Moscow) (2015);80(10):1503–1521.

8. Achari AE, Jain SK. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. Int J Mol Sci. 2017;18(6):1321. DOI: 0.3390/ijms18061321

9. Rubina KA, Semina EV, Balatskaya MN, Plekhanova OS, Tkachuk VA. Mechanisms of regulation of the targeted grown of nerves and vessels by components of the fibrinolytic system and gpi-anchored navigation receptors. Neuroscience and Behavioral Physiology. 2020;50(2): 217–230. DOI: 10.1007/s11055-019-00890-1

10. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762–769. DOI: 10.1038/nature01705

11. Sysoeva V, Semina E, Klimovich P, Kulebyakin K, Dzreyan V, Sotskaya E, et al. T-Cadherin Modulates Adipogenic Differentiation in Mesenchymal Stem Cells: Insights into Ligand Interactions. Front Cell Dev Biol. 2024;12:1446363. DOI: 10.3389/fcell.2024.1446363

12. Popov VS, Brodsky IB, Balatskaya MN, Balatskiy AV, Ozhimalov ID, Kulebyakina MA, et al. T-cadherin deficiency is associated with increased blood pressure after physical activity. International Journal of Molecular Sciences. 2023;24(18) :14204. DOI: 10.3390/ijms241814204

13. Cao Z, Umek RM, McKnight SL. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev. 1991;5(9):1538–1552. DOI: 10.1101/gad.5.9.1538

14. Moseti D, Regassa A, Kim WK. Molecular Regulation of Adipogenesis and Potential AntiAdipogenic Bioactive Molecules. Int J Mol Sci. 2016;17(1):124. DOI: 10.3390/ijms17010124

15. Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol. 2011;12(11):722–734. DOI: 10.1038/nrm3198

16. Riener MO, Nikolopoulos E, Herr A, Wild PJ, Hausmann M, Wiech T, et al. Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q. Hum Pathol. 2008;39(11):1621–1629. DOI: 10.1016/j.humpath.2008.02.016

17. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 2001;61(11):4556–4560.

18. Qian ZR, Sano T, Yoshimoto K, Asa SL, Yamada S, Mizusawa N, et al. Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol. 2007;20(12):1269– 1277. DOI: 10.1038/modpathol.3800965

19. Ogama Y, Ouchida M, Yoshino T, Ito S, Takimoto H, Shiote Y, et al. Prevalent hypermethylation of the CDH13 gene promoter in malignant B cell lymphomas. Int J Oncol. 2004;25(3):685–691.

20. Sun D, Zhang Z, Van doN, Huang G, Ernberg I, Hu L. Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker.OralOncol. (2007)43(1):82–87. DOI: 10.1016/j.oraloncology.2006.01.007

21. Zucchini C, Bianchini M, Valvassori L, Perdichizzi S, Benini S, Manara MC, et al. Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene. Bone. 2004;34(4):672–679. DOI: 10.1016/j.bone.2003.12.008

22. Philippova M, Joshi MB, Kyriakakis E, Pfaff D, Erne P, Resink TJ. A guide and guard: the many faces of T-cadherin. Cell Signal. 2009;21(7):1035–1044. DOI: 10.1016/j.cellsig.2009.01.035

23. Suehiro Y, Okada T, Okada T, Anno K, Okayama N, Ueno K, et al. Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clin Cancer Res. 2008:14(11):3354–3361. DOI: 10.1158/1078-0432.CCR-07-4609

24. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zöchbauer-Müller S, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001;61(24):8659–8663.

25. Hebbard L, Ranscht B. Multifaceted roles of adiponectin in cancer. Best Pract Res Clin Endocrinol Metab. 2014;28(1):59–69. DOI: 10.1016/j.beem.2013.11.005

26. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547–594. DOI: 10.1210/er.2011-1015

27. Hefetz-Sela S, Scherer PE. Adipocytes: impact on tumor growth and potential sites for therapeutic intervention. Pharmacol Ther. 2013;138(2):197–210. DOI: 10.1016/j.pharmthera.2013.01.008

28. Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res. 2005;11(10):3642–3646. DOI: 10.1158/10780432.CCR-04-1868

29. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11(2 Pt 1):466–472.

30. Ye P, Xi Y, Huang Z, Xu P. Linking Obesity with Colorectal Cancer: Epidemiology and Mechanistic Insights. Cancers (Basel). 2020;12(6):1408. DOI: 10.3390/cancers12061408

31. Moon HS, Liu X, Nagel JM, Chamberland JP, Diakopoulos KN, Brinkoetter MT, et al. Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut. 2013;62(4):561–570. DOI: 10.1136/gutjnl-2012-302092

32. Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, et al. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer. 2011;129(9):2226–2235. DOI: 10.1002/ijc.25861

33. Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009;20(5):625–633. DOI: 10.1007/s10552-008-9273-z

34. Yoneda K, Tomimoto A, Endo H, Iida H, Sugiyama M, Takahashi H, et al. Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue. Oncol Rep. 2008;20(3):479–483.

35. Byeon JS, Jeong JY, Kim MJ, Lee SM, Nam WH, Myung SJ, et al. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer. 2010;127(12):2758– 2767. DOI: 10.1002/ijc.25301

36. Duan BS, Xie LF, Wang Y. Aberrant Methylation of T-cadherin Can Be a Diagnostic Biomarker for Colorectal Cancer. Cancer Genomics Proteomics. 2017;14(4):277–284. DOI: 10.21873/cgp.20038